Wird geladen...
Lenalidomide for refractory cutaneous manifestations of paediatric systemic lupus erythematosus
OBJECTIVE: Cutaneous manifestations of paediatric systemic lupus erythematosus (pSLE) cause significant morbidity. Lenalidomide, a thalidomide analogue, has shown promise treating cutaneous LE (CLE) in adults. Our objective was to evaluate lenalidomide's efficacy and safety in treating refracto...
Gespeichert in:
| Veröffentlicht in: | Lupus |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5388573/ https://ncbi.nlm.nih.gov/pubmed/27837194 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0961203316676377 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|